DISA Limited's (SGX:532) subsidiary, Digital Life Line, has partnered with the National University Hospital (Singapore) and the National University of Singapore to commercialize the Mobile Imaging Device for Anterior Segment (MIDAS), a portable cataract screening device, according to a Wednesday filing with the Tokyo Stock Exchange.
The AI-powered tool, designed for use with smartphones, enables quick, community-based cataract detection, targeting early intervention, the filing said.
Chief Executive Officer Eddie Chng said the device combines AI algorithms with ease of use, delivering results in 10 seconds. The company aims to expand the device's reach regionally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.